Takeda Gmbh

Altana Pharma Ag

Nycomed Gmbh

Astrazeneca Ab

Byk Gulden Lomberg Chemische Fabrik Gmbh

Hartmut Ney

Rango Dietrich

Rudolf Linder

Klaus Eistetter

Marc Schiller

Isabel Anstett-Klein

Manfred Hartmann

Sabine Schaefer-Preuss

Sabine Schäfer-Preuss

Isabel Anstett

Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.

Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient

Dosage forms for oral administration of the magnesium salt of (S)-pantoprazole are described.

Dosage form containing (S)-pantoprazole as active ingredient

Dosage forms for the oral administration of the magnesium salt of pantoprazole are described.

Dosage form containing pantoprazole as active ingredient

The invention relates to an oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles and their salts, which comprises the active compound together with tablet disintegrants and is provided with a film coating customary per se for sustained-release compositions.

Oral administration form for pyridin-2-ylmethylsulfinyl-1H benzimidazoles

Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient

The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation, an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohols, triglycerides, partial triglycerides and fatty acid esters.

Pharmaceutical preparation comprising an active dispersed on a matrix

Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles

The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

A rapidly disintegrating tablet for oral administration of acid-labile active ingredients is described. The rapidly disintegrating tablet for oral administration of an acid-labile active ingredient comprises a plurality of individual active ingredient units together with pharmaceutical excipients, where the acid-labile active ingredient is present in the individual active ingredient units in a matrix composed of a mixture comprising at least one solid paraffin and one or more substances from the group of fatty alcohol, triglyceride and fatty acid ester, and where excipients which, on oral intake of the tablet, bring about rapid disintegration of the tablet are present.

Growing community of inventors

Constance, Germany

Hartmut Ney